HALO vs. LLY: Halozyme Therapeutics vs. Eli Lilly Stock Comparison
How do Halozyme Therapeutics (HALO) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while LLY is classified in Pharmaceuticals.
| Profile Item | HALO | LLY |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 11.81 billion USD | 1,206.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | March 16, 2004 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | LLY |
|---|---|---|
| Total Return (1Y) | 50.94% | 52.36% |
| Total Return (3Y, Annualized) | 41.08% | 34.18% |
| Total Return (5Y, Annualized) | 21.68% | 41.08% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 35.34% |
| Beta (5Y) | 0.96 | 0.40 |
| Max Drawdown (5Y) | -49.06% | -34.48% |
| Avg. Volume (3M) | 2.29M | 2.52M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | LLY |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 1.36 |
| Sortino Ratio (1Y) | 1.78 | 2.29 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Eli Lilly (LLY) at 86.02% also sits in the top quartile.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Halozyme Therapeutics (HALO) at 26.93% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Halozyme Therapeutics (HALO) at 59.84% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | LLY |
|---|---|---|
| ROE (TTM) | 216.38% | 86.02% |
| ROA (TTM) | 22.42% | 21.06% |
| Net Margin (TTM) | 26.93% | 31.90% |
| Operating Margin (TTM) | 59.84% | 53.66% |
| Gross Margin (TTM) | 77.74% | 83.63% |
Growth
Revenue Growth
Both Halozyme Therapeutics (HALO) at 37.55% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Halozyme Therapeutics (HALO) at -25.36% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | HALO | LLY |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | 44.70% |
| Revenue Growth (3Y CAGR) | 28.38% | 31.69% |
| EPS Growth (YoY) | -25.36% | 95.99% |
| EPS Growth (3Y CAGR) | 21.14% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Eli Lilly (LLY) carries debt-to-equity ratio of 1.23 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | LLY |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 1.39 |
| Debt / Equity (MRQ) | -- | 1.23 |
| Net Debt / EBITDA | 1.90 | 0.96 |
Dividends
Dividend Yield (TTM)
Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.49% |
| Dividend Payout Ratio (TTM) | 0.00% | 21.71% |
Valuation
P/E Ratio (TTM)
Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Eli Lilly (LLY) reports 29.96, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | LLY |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | 43.95 |
| P/S Ratio (TTM) | 6.55 | 13.95 |
| P/B Ratio (MRQ) | -213.67 | 29.96 |
| Free Cash Flow Yield (TTM) | 3.48% | 0.77% |